Agios Pharmaceuticals Inc (STU:8AP)
€ 34.2 -3 (-8.06%) Market Cap: 1.93 Bil Enterprise Value: 1.03 Bil PE Ratio: 3.01 PB Ratio: 1.20 GF Score: 50/100

Q4 2018 Agios Pharmaceuticals Inc Earnings Call Transcript

Feb 14, 2019 / 01:00PM GMT
Release Date Price: €48.46 (+0.04%)
Operator

Good morning, and welcome to Agios' Fourth Quarter 2018 Conference Call. (Operator Instructions) Please be advised that this call is being recorded at Agios' request.

I would now like to turn the call over to Kendra Adams, Senior Director, Investor and Public Relations.

Kendra Adams
Agios Pharmaceuticals, Inc. - Senior Director of Investor & Public Relations

Thank you, Shannon. Good morning, everyone, and welcome to Agios' Fourth Quarter 2018 Conference Call. You can access slides for today's call by going to the Investors section of our website, agios.com.

With me on the call today are Dr. Jackie Fouse, our Chief Executive Officer, who will review key business updates and milestones for 2019; Dr. Chris Bowden, our Chief Medical Officer, who will provide an update on our clinical development activities; Steve Hoerter, our Chief Commercial Officer, who will provide an update on the launch of TIBSOVO; and Andrew Hirsch, our Chief Financial Officer, who will summarize our fourth quarter and full year 2018 financial results. Dr. Scott Biller

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot